



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	373063	Mg Trilogy
ARTG entry for	Medicine Listed	
Sponsor	Greal Labs Pty Ltd	
Postal Address	PO Box 193, Fitzroy, VIC, 3065 Australia	
ARTG Start Date	18/08/2021	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Mg Trilogy

Product Type	Single Medicine Product	Effective Date	5/12/2022
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

- Maintain/support general health and wellbeing
- Maintain/support bone health
- Maintain/support bone mass/density/integrity
- Maintain/support cardiovascular system health when dietary intake is inadequate
- Decrease/reduce/relieve muscle cramps when dietary intake is inadequate
- Helps decrease/reduce/relieve mild muscle spasms/twitches when dietary intake is inadequate
- Maintain/support muscle health
- Maintain/support muscle function
- Enhance/improve/promote/increase muscle relaxation
- Aid/assist/helps post exercise recovery
- Maintain/support (state vitamin/mineral/nutrient) levels in the body
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
- Decrease/reduce/relieve nervous tension/unrest
- Maintain/support nervous system health when dietary intake is inadequate
- Decrease/reduce/relieve sleeplessness
- Enhance/improve/promote/increase sleep quality/deep sleep

Indication Requirements

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).



Australian Government
Department of Health and Aged Care
 Therapeutic Goods Administration

Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.

Product presentation must not imply or refer to serious cardiovascular conditions.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

magnesium citrate	138.23 mg
Equivalent: magnesium	20.73 mg
magnesium glycerophosphate	138.23 mg
Equivalent: magnesium	15.2 mg
magnesium glycinate	576.43 mg
Equivalent: magnesium	69.17 mg

Other Ingredients (Excipients)

- carrageenan
- colloidal anhydrous silica
- hypromellose
- magnesium stearate
- microcrystalline cellulose
- potassium acetate
- purified water

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.